The relationship between the local and systemic inflammatory responses and survival in patients undergoing resection for localized renal cancer

Article English OPEN
Lamb, G.W. ; McArdle, P.A. ; Ramsey, S. ; McNichol, A.M. ; Edwards, J. ; Aitchison, M. ; McMillan, D.C. (2008)

To examine the relationship between the systemic inflammatory response (C-reactive protein, CRP), tumour interleukin-6 receptor and cyclooxygenase (COX)-2 expression, tumour T-lymphocytic (CD4+, CD8+) infiltration and cancer survival in patients undergoing resection for renal cell carcinoma (RCC), as both the local and systemic inflammatory responses appear to predict the outcome in these patients.\ud <b>PATIENTS AND METHODS:</b>\ud \ud The study included 60 patients undergoing nephrectomy for localized RCC. Pre-operative circulating CRP levels were measured and tumour interleukin-6 receptor and COX-2 expression, tumour CD4+ and CD8+ T lymphocytes were assessed using immunohistochemical analysis.\ud <b>RESULTS:</b>\ud \ud The median follow-up was 78 months, with 14 patients relapsing from their disease and nine cancer-specific deaths. On univariate and multivariate survival analysis, tumour stage and grade and CRP levels were identified as significant factors associated with relapse-free and cancer-specific survival. There was a significant direct relationship between Fuhrman grade and CD4+ T-lymphocytic infiltrate (P > 0.05). An increase in tumour expression of interleukin-6 receptor was weakly associated with an increase in tumour CD8+ T-lymphocytic infiltration (P = 0.057). An increase in tumour CD4+ T-lymphocytic infiltration was associated with an increase in CD8+ T-lymphocytic infiltration (P > 0.01).\ud <b>CONCLUSIONS:</b>\ud \ud The present results suggest that tumour-based factors such as interleukin-6 receptor and COX-2 expression or T-lymphocytic subset infiltration are subordinate to systemic factors such as CRP level in determining survival in patients with localized RCC.
  • References (4)

    1 O'Byrne KJ, Dalgleish AG. Chronic immune activation and inflammation as the cause of malignancy. Br J Cancer 2001: 85: 473-83.

    2 Coussens LM, Werb Z. Inflammation and cancer. Nature 2002: 420: 860-7.

    3 Vakkila J, Lotze MT. Inflammation and necrosis promote tumour growth. Nat Rev Immunol 2004: 4: 641-8.

    4 O'Gorman P, McMillan DC, McArdle CS. Prognostic factors in advanced gastrointestinal cancer patients with weight loss. Nutr Cancer 2000: 37: 36-40.

  • Metrics
    No metrics available
Share - Bookmark